1. Validation of a clinical and genetic model for predicting severe COVID-19
- Author
-
Richard Allman, Gillian Dite, Henry Wiersma, Robert Warmerdam, Irene Van Blokland, Pauline Lanting, Erika Spaeth, Nicholas Murphy, Life Course Epidemiology (LCE), Groningen Research Institute for Asthma and COPD (GRIAC), Value, Affordability and Sustainability (VALUE), Research programme EEF, Stem Cell Aging Leukemia and Lymphoma (SALL), and Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI)
- Subjects
validation ,risk prediction ,Infectious Diseases ,Epidemiology ,risk factors ,severe COVID-19 ,single-nucleotide polymorphism - Abstract
Using nested case–control data from the Lifelines COVID-19 cohort, we undertook a validation study of a clinical and genetic model to predict the risk of severe COVID-19 in people with confirmed COVID-19 and in people with confirmed or self-reported COVID-19. The model performed well in terms of discrimination of cases and controls for all ages (area under the receiver operating characteristic curve (AUC) = 0.680 for confirmed COVID-19 and AUC = 0.689 for confirmed and self-reported COVID-19) and in the age group in which the model was developed (50 years and older; AUC = 0.658 for confirmed COVID-19 and AUC = 0.651 for confirmed and self-reported COVID-19). There was no evidence of over- or under-dispersion of risk scores but there was evidence of overall over-estimation of risk in all analyses (all P < 0.0001). In the light of large numbers of people worldwide remaining unvaccinated and continuing uncertainty regarding vaccine efficacy over time and against variants of concern, identification of people at high risk of severe COVID-19 may encourage the uptake of vaccinations (including boosters) and the use of non-pharmaceutical inventions.
- Published
- 2022